2 growth stars to perk up your portfolio

Here are two very different shares, both of which show exciting growth prospects.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Growth comes in many forms, and here I’m looking at two very different companies showing growth prospects.

Electronics recovery

Shares in TT Electronics (LSE: TTG) haven’t really gone anywhere over the past couple of years, but they picked up 3.5% on the day that 2016 results were announced, to reach 169p.

The manufacturer of electronics components reported a 40% rise in underlying pre-tax profit to £26.9m (up 20% at constant exchange rates), with underlying earnings per share up 36% and the dividend lifted modestly from 5.5p to 5.6p.

That beat expectations, with chief executive Richard Tyson speaking of “excellent” free cash flow. He added that “We have a clear and realistic strategy for TT to focus on structural growth markets where there is increasing electronic content“, and an ever-industrializing world can only help in that quest.

One thing that does concern me a little is net debt standing at £55.4m. While that’s probably not a big problem, for a company with a market cap of approximately £250m and in a low-margin business, I’d like to see it coming down.

Still, the results confirm that the expected reversal in TT’s fortunes is under way, and that the earnings falls that have blighted the previous two years are well into reversal. Analysts have a modest further EPS gain of 5% penciled in for 2017, though with 2016 results better than I expected I wouldn’t be surprised to see that rerated upwards now.

Forecasts suggest a P/E of 12 by 2018, and with the dividend yield approaching a very respectable 4% yield, I see TT as a decent growth opportunity.

Pottery success

Portmeirion Group (LSE: PMP) is a very different company, making a range of tableware products — as well as the Portmeirion brand itself, the group owns Spode and Royal Worcester.  It also owns Wax Lyrical, which produces candles, reed diffusers, scent oils and sprays.

The shares had a dreadful 2016, losing 40% of their value between a peak in May that year and a low point in October.

And 2016 results confirmed the expected falls, with pre-tax profit down 9.7% to £7.8m and earnings per share down a similar proportion to 59.6p. But it’s looking like a one-off, with the company putting its profit fall down to “increased amortisation and depreciation as a consequence of the Wax Lyrical acquisition and a full year’s depreciation of our new kiln“.

And with chairman Dick Steele telling us it was the firm’s “eighth consecutive year of record revenue“, and the dividend actually lifted by 7.5% to 32.25p per share, were the shares oversold in 2016?

Yes, I think they were, and at 960p today the price has already recovered 28% since their low last year. Looking forward to forecasts for this year and next, we see an expected resumption of EPS growth adding 13% to the bottom line this year and another 11% next.

The company’s very well covered dividend looks set to keep rising too, and should provide yields of around 3.5%. Year-end net debt at £2.3m is nothing to worry about, and it doesn’t damage the attractiveness of forward P/E multiples for this year and next of 14.3 and 12.9 for me.

While the screaming bargain days of late 2016 are over, I still think we see a lower-than-average valuation for a better-than-average company. And while PEG ratios of a little over one might not set the rapid-growth bells ringing, I think we’re in for slow and steady growth coupled with reliable and rising dividends. Can’t be bad.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended Portmeirion Group. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

How much passive income could I make for every £1,000 invested in Aviva shares?

Even a relatively small investment in Aviva shares could generate much greater passive income, particularly if the dividends are reinvested…

Read more »

Close-up of British bank notes
Investing Articles

I’m considering 100 shares in this FTSE 250 gem to aim for £300 a month in dividends

Mark Hartley outlines why a lesser-known banking stock from the FTSE 250's worth considering for an income portfolio in 2024.

Read more »

Investing Articles

History suggests these UK shares might soar if interest rates are cut in August

Some UK shares could rocket if interest rates fall from its 5.25% high next month. And there's one our writer…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

Here’s why H1 results could boost the AstraZeneca share price

The AstraZeneca share price has been a success story in the past five years. With H1 results due, can it…

Read more »

Investing Articles

£17,365 in savings? Here’s how I’d use it to target a £6,700-a-month passive income

Here's how a lump sum investment could pave the way for me to make a four-figure monthly passive income in…

Read more »

Investing Articles

Down more than 10% in 6 months, Fools are backing these 5 UK stocks to reverse that – and then some! – by 2025

Some of our UK free-site writers have put forward their candidates for turnaround stocks!

Read more »

Investing Articles

Down 23%! Should I buy more CrowdStrike shares for my Stocks and Shares ISA?

Sometimes bad news can be good news for long-term investors. But is that the case for CrowdStrike in relation to…

Read more »

Investing Articles

2 UK shares near 52-week lows I’m considering snapping up

These UK shares are loitering near, or at, 52-week lows. Are these prime opportunities for our writer to boost her…

Read more »